Polymer-free Drug-Coated Coronary Stents.

By H. Tomoda. New England Journal of Medicine, 2016

603 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/bfaded29d28335fe54afc2ec63413930c9bc29a4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. P. O'Gara
2. A. Goette
3. Jose Luis Zamorano
4. M. Mack
5. L. Fleisher
6. Stephan Windecker

Citations in the corpus

• [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, methodology): “1-month DAPT following implantation of zotarolimus-eluting Endeavour sprint stent or drug-coated stent reduced risks of re-intervention, myocardial infarction and inconsistently of stent thrombosis compared to baremetal stent under similar DAPT duration [129, 130].”
• 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, background): “In a study of a novel polymer-free and carrierfree drug-coated stent in patients at high risk of bleeding complications, by study protocol, DAPT was continued for only 1 month.(117) These stents have not been included in the studies of shorter- or longer-duration (prolonged/extended) DAPT discussed ”
• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, background): “There is no reason anymore to opt for a BMS as a strategy to reduce DAPT duration.(32,314) Sole balloon angioplasty or bypass surgery should be considered as an alternative in patients in need for chronic anticoagulation due to the reduced need for long-term dual or triple therapy.”
• 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, background): “In a study of a novel polymer-free and carrier-free drug-coated stent in patients at high risk of bleeding complications, by study protocol, DAPT was continued for only 1 month (117).”